Scientists report landmark "evolutionary double-bind" strategy to overcome treatment resistance in prostate cancer.

HOUSTON, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (BPTH),, a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a ...

Researchers at The University of Texas MD Anderson Cancer Center have developed a new computational approach designed to ...

Scientists at McGill University and the Rosalind and Morris Goodman Cancer Institute have developed a new way to deliver ...

UConn Center on Aging researchers have published a new editorial in the journal Aging titled "Polyploidy-induced senescence: Linking development, differentiation, repair, and (possibly) cancer?" In ...

A team of researchers led by Stanford University and San Diego-based Boundless Bio have identified an oral small molecule that specifically targets extrachromosomal DNA (ecDNA) in cancer cells, ...

Scientists have uncovered an unexpected reason why some cancers return after initially responding to treatment.

Genetic ancestry may play a key role in how acral melanoma, a rare and aggressive type of skin cancer, develops and behaves, ...

COLORADO SPRINGS, CO, UNITED STATES, January 14, 2026 /EINPresswire.com/ — Lahjavida Bio, a biotechnology company pioneering a new class of tumor-targeted small ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic proteins, ...